Cite
HARVARD Citation
Ehrhardt, M. et al. (2018). The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma. Journal of cellular and molecular medicine. 22 (4), pp. 2153-2161. [Online].